These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

457 related items for PubMed ID: 18366284

  • 1. The Early Prostate Cancer program: bicalutamide in nonmetastatic prostate cancer.
    Iversen P, Roder MA.
    Expert Rev Anticancer Ther; 2008 Mar; 8(3):361-9. PubMed ID: 18366284
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide Early Prostate Cancer programme at a median follow-up of 9.7 years.
    Iversen P, McLeod DG, See WA, Morris T, Armstrong J, Wirth MP, Casodex Early Prostate Cancer Trialists' Group.
    BJU Int; 2010 Apr; 105(8):1074-81. PubMed ID: 22129214
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup.
    Iversen P, Tyrrell CJ, Kaisary AV, Anderson JB, Van Poppel H, Tammela TL, Chamberlain M, Carroll K, Melezinek I.
    J Urol; 2000 Nov; 164(5):1579-82. PubMed ID: 11025708
    [Abstract] [Full Text] [Related]

  • 7. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy.
    Morote J, Orsola A, Planas J, Trilla E, Raventós CX, Cecchini L, Catalán R.
    J Urol; 2007 Oct; 178(4 Pt 1):1290-5. PubMed ID: 17698136
    [Abstract] [Full Text] [Related]

  • 8. Is the efficacy of hormonal therapy affected by lymph node status? data from the bicalutamide (Casodex) Early Prostate Cancer program.
    Iversen P, Wirth MP, See WA, McLeod DG, Klimberg I, Gleason D, Chodak G, Montie J, Tyrrell C, Wallace DM, Delaere KP, Lundmo P, Tammela TL, Johansson JE, Morris T, Carroll K, Casodex Early Prostate Cancer Trialists' Group.
    Urology; 2004 May; 63(5):928-33. PubMed ID: 15134983
    [Abstract] [Full Text] [Related]

  • 9. Bicalutamide.
    Prescrire Int; 2007 Apr; 16(88):67. PubMed ID: 17458049
    [Abstract] [Full Text] [Related]

  • 10. Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration.
    Tyrrell CJ, Iversen P, Tammela T, Anderson J, Björk T, Kaisary AV, Morris T.
    BJU Int; 2006 Sep; 98(3):563-72. PubMed ID: 16771791
    [Abstract] [Full Text] [Related]

  • 11. Maximal androgen blockade for advanced prostate cancer.
    Klotz L.
    Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):331-40. PubMed ID: 18471790
    [Abstract] [Full Text] [Related]

  • 12. The addition of bicalutamide 150 mg to radiotherapy significantly improves overall survival in men with locally advanced prostate cancer.
    See WA, Tyrrell CJ, CASODEX Early Prostate Cancer Trialists' Group.
    J Cancer Res Clin Oncol; 2006 Aug; 132 Suppl 1():S7-16. PubMed ID: 16896884
    [Abstract] [Full Text] [Related]

  • 13. Duration of androgen suppression in the treatment of prostate cancer.
    Bolla M, de Reijke TM, Van Tienhoven G, Van den Bergh AC, Oddens J, Poortmans PM, Gez E, Kil P, Akdas A, Soete G, Kariakine O, van der Steen-Banasik EM, Musat E, Piérart M, Mauer ME, Collette L, EORTC Radiation Oncology Group and Genito-Urinary Tract Cancer Group.
    N Engl J Med; 2009 Jun 11; 360(24):2516-27. PubMed ID: 19516032
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Bicalutamide ('Casodex') 150 mg in addition to standard care in patients with nonmetastatic prostate cancer: updated results from a randomised double-blind phase III study (median follow-up 5.1 y) in the early prostate cancer programme.
    Wirth M, Tyrrell C, Delaere K, Sánchez-Chapado M, Ramon J, Wallace DM, Hetherington J, Pina F, Heyns C, Borchers T, Morris T, Armstrong J, 'Casodex' Early Prostate Cancer Trialists' Group.
    Prostate Cancer Prostatic Dis; 2005 Jun 11; 8(2):194-200. PubMed ID: 15931272
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program.
    See WA, Wirth MP, McLeod DG, Iversen P, Klimberg I, Gleason D, Chodak G, Montie J, Tyrrell C, Wallace DM, Delaere KP, Vaage S, Tammela TL, Lukkarinen O, Persson BE, Carroll K, Kolvenbag GJ, Casodex Early Prostate Cancer Trialist Group.
    J Urol; 2002 Aug 11; 168(2):429-35. PubMed ID: 12131282
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. The patient's choice of androgen-deprivation therapy in locally advanced prostate cancer: bicalutamide, a gonadotrophin-releasing hormone analogue or orchidectomy.
    Nyman CR, Andersen JT, Lodding P, Sandin T, Varenhorst E.
    BJU Int; 2005 Nov 11; 96(7):1014-8. PubMed ID: 16225519
    [Abstract] [Full Text] [Related]

  • 20. Gynecomastia and breast pain induced by adjuvant therapy with bicalutamide after radical prostatectomy in patients with prostate cancer: the role of tamoxifen and radiotherapy.
    Di Lorenzo G, Perdonà S, De Placido S, D'Armiento M, Gallo A, Damiano R, Pingitore D, Gallo L, De Sio M, Autorino R.
    J Urol; 2005 Dec 11; 174(6):2197-203. PubMed ID: 16280763
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.